Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Agenus Announces Virtual 2026 Annual Shareholders Meeting
-
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
-
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
-
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
-
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
-
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
-
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
-
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Trading Information
- Previous Close Price
- $3.25
- Day Range
- $2.96–3.05
- 52-Week Range
- $2.77–7.32
- Bid/Ask
- $2.93 / $2.99
- Shares Outstanding
- 41.64M
- Market Cap
- $124.09M
- Volume/Avg
- 1,195 / 837,038
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 81
- Website
- https://www.agenusbio.com
Valuation
|
Metric
|
AGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.88 |
Price/Cash Flow | — |
Price/Earnings
AGEN
Financial Strength
|
Metric
|
AGEN
|
|---|---|
Quick Ratio | 0.20 |
Current Ratio | 0.38 |
Interest Coverage | 2.09 |
Quick Ratio
AGEN
Profitability
|
Metric
|
AGEN
|
|---|---|
Return on Assets (Normalized) | −34.67% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vcrdjhqx | Bqtwz | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vldhszrrh | Lndsbz | $64B | |||
| argenx SE ADR
ARGX
| Fypjwgrqh | Pqn | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zchqctqm | Rtvfwz | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Lhjlnxbjnc | Gryjpb | $24B | |||
| BioNTech SE ADR
BNTX
| Tnltvvsrz | Xtjjr | $23B | |||
| Incyte Corp
INCY
| Ttwqdrg | Jlkc | $22B | |||
| Moderna Inc
MRNA
| Bvttnjwly | Srhfs | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Hrptrgt | Xfqzl | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Hyltbbxdp | Rjng | $13B |
United States